• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Feasibility of redo-TAVI in the self-expanding ACURATE neo2 valve: a computed tomography study.自膨式 ACURATE neo2 瓣膜再次经导管主动脉瓣置换术的可行性:一项 CT 研究。
EuroIntervention. 2024 Nov 18;20(22):1405-1415. doi: 10.4244/EIJ-D-24-00367.
2
Feasibility of redo-TAVI in self-expanding Evolut valves: a CT analysis from the Evolut Low Risk Trial substudy.自膨式 Evolut 瓣膜再次经导管主动脉瓣置换术的可行性:来自 Evolut 低危试验亚组研究的 CT 分析。
EuroIntervention. 2023 Jul 17;19(4):e330-e339. doi: 10.4244/EIJ-D-22-01125.
3
Redo-TAVI with the SAPIEN 3 valve in degenerated calcified CoreValve/Evolut explants.再次行经导管主动脉瓣置换术(TAVI),使用 SAPIEN 3 瓣膜置换衰败且严重钙化的 CoreValve/Evolut 瓣膜。
EuroIntervention. 2024 Nov 18;20(22):1390-1404. doi: 10.4244/EIJ-D-24-00619.
4
TAVI with the ACURATE neo2 in severe bicuspid aortic valve stenosis: the Neo2 BAV Registry.使用ACURATE neo2经导管主动脉瓣植入术治疗重度二叶式主动脉瓣狭窄:Neo2二叶式主动脉瓣注册研究
EuroIntervention. 2025 Jan 20;21(2):e130-e139. doi: 10.4244/EIJ-D-24-00869.
5
The Coronary Access After TAVI (CAvEAT) Study: A Prospective Registry of CA After TAVR.经导管主动脉瓣置入术后冠状动脉通路(CAvEAT)研究:一项经导管主动脉瓣置换术后冠状动脉通路的前瞻性登记研究
JACC Cardiovasc Interv. 2025 Jun 23;18(12):1571-1583. doi: 10.1016/j.jcin.2025.05.002.
6
Impact of Calcified Raphe on TAVR in Bicuspid Patients: Predicting Redo-TAVR Feasibility and Virtual Planning Implications.钙化中隔对二叶式患者经导管主动脉瓣置换术的影响:预测再次经导管主动脉瓣置换术的可行性及虚拟规划的意义
Circ Cardiovasc Interv. 2025 Jun;18(6):e014802. doi: 10.1161/CIRCINTERVENTIONS.124.014802. Epub 2025 Apr 22.
7
SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial.经导管主动脉瓣植入术使用SAPIEN 3与Myval经导管心脏瓣膜对比研究(COMPARE-TAVI 1):一项多中心、随机、非劣效性试验
Lancet. 2025 Apr 19;405(10487):1362-1372. doi: 10.1016/S0140-6736(25)00106-0. Epub 2025 Apr 2.
8
Redo-TAVR Feasibility After SAPIEN 3 Stratified by Implant Depth and Commissural Alignment: A CT Simulation Study.经 SAPIEN 3 分层的植入深度和交界对位后再次行经导管主动脉瓣置换术的可行性:CT 模拟研究。
Circ Cardiovasc Interv. 2024 Mar;17(3):e013766. doi: 10.1161/CIRCINTERVENTIONS.123.013766. Epub 2024 Mar 19.
9
Chimney stenting for preventing coronary obstruction in redo-TAVI with balloon-expandable valves within self-expanding valves.烟囱式支架置入术预防在自膨胀瓣膜内置入球囊扩张瓣膜的再次经导管主动脉瓣置换术中的冠状动脉阻塞。
EuroIntervention. 2025 Jun 16;21(12):e692-e703. doi: 10.4244/EIJ-D-24-01018.
10
Permanent pacemaker implantation following transcatheter aortic valve implantation using self-expandable, balloon-expandable, or mechanically expandable devices: a network meta-analysis.使用自膨胀、球囊扩张或机械扩张装置经导管主动脉瓣植入术后永久性起搏器植入:一项网状Meta分析
Europace. 2021 Dec 7;23(12):1998-2009. doi: 10.1093/europace/euab209.

引用本文的文献

1
Redo-Transcatheter Aortic Valve Replacement Procedural Optimization and Patient Selection: From Bench to Clinical Practice.再次经导管主动脉瓣置换术的手术优化与患者选择:从实验台到临床实践
J Clin Med. 2025 Apr 17;14(8):2770. doi: 10.3390/jcm14082770.

本文引用的文献

1
Redo-TAVI with a balloon-expandable valve and the impact of index transcatheter aortic valve design.使用球囊扩张瓣膜的再次经导管主动脉瓣置换术及初次经导管主动脉瓣设计的影响
EuroIntervention. 2023 Nov 17;19(9):714-716. doi: 10.4244/EIJ-D-23-00363.
2
Feasibility of Coronary Access Following Redo-TAVR for Evolut Failure: A Computed Tomography Simulation Study.经 Evolut 失败的再次 TAVR 后行冠状动脉入路的可行性:一项计算机断层扫描模拟研究。
Circ Cardiovasc Interv. 2023 Nov;16(11):e013238. doi: 10.1161/CIRCINTERVENTIONS.123.013238. Epub 2023 Nov 21.
3
Challenges and Future Directions in Redo Aortic Valve Reintervention After Transcatheter Aortic Valve Replacement Failure.经导管主动脉瓣置换失败后再次行主动脉瓣干预的挑战与未来方向
Circ Cardiovasc Interv. 2023 Nov;16(11):e012966. doi: 10.1161/CIRCINTERVENTIONS.123.012966. Epub 2023 Nov 21.
4
Comparison of BASILICA and Balloon-Assisted BASILICA Coronary Protection for Redo-TAVR: Insights From Bench Testing.BASILICA与球囊辅助BASILICA在经导管主动脉瓣置换术(redo-TAVR)冠状动脉保护中的比较:来自台架测试的见解
JACC Cardiovasc Interv. 2023 Jun 12;16(11):1431-1433. doi: 10.1016/j.jcin.2023.04.031.
5
Explant vs Redo-TAVR After Transcatheter Valve Failure: Mid-Term Outcomes From the EXPLANTORREDO-TAVR International Registry.经导管瓣膜失效后取出瓣膜与再次经导管主动脉瓣置换术:EXPLANTORREDO-TAVR国际注册研究的中期结果
JACC Cardiovasc Interv. 2023 Apr 24;16(8):927-941. doi: 10.1016/j.jcin.2023.01.376.
6
BASILICA Procedure Prior to Valve-in-Valve TAVR in a Supra-Annular TAV Prosthesis.在瓣中瓣经导管主动脉瓣置换术(TAVR)治疗瓣环上TAV人工瓣膜之前的BASILICA手术。
JACC Case Rep. 2023 Feb 16;11:101777. doi: 10.1016/j.jaccas.2023.101777. eCollection 2023 Apr 5.
7
Feasibility of redo-TAVI in self-expanding Evolut valves: a CT analysis from the Evolut Low Risk Trial substudy.自膨式 Evolut 瓣膜再次经导管主动脉瓣置换术的可行性:来自 Evolut 低危试验亚组研究的 CT 分析。
EuroIntervention. 2023 Jul 17;19(4):e330-e339. doi: 10.4244/EIJ-D-22-01125.
8
A bench study of balloon-expandable valves for the treatment of self-expanding valve failure.球囊扩张瓣在自膨式瓣膜衰败治疗中的应用的台架研究。
EuroIntervention. 2023 May 15;19(1):93-102. doi: 10.4244/EIJ-D-22-00769.
9
Procedural considerations for transcatheter aortic valve-in-valve implantation in a degenerated ACURATE neo prosthesis.在退化的ACURATE neo人工心脏瓣膜中进行经导管主动脉瓣中瓣植入的操作注意事项。
EuroIntervention. 2023 Apr 24;18(17):1436-1438. doi: 10.4244/EIJ-D-22-00740.
10
Transcatheter Aortic Valve Replacement in Failed Transcatheter Bioprosthetic Valves.经导管主动脉瓣置换术治疗失败的经导管生物瓣。
JACC Cardiovasc Interv. 2022 Sep 26;15(18):1777-1793. doi: 10.1016/j.jcin.2022.07.035.

自膨式 ACURATE neo2 瓣膜再次经导管主动脉瓣置换术的可行性:一项 CT 研究。

Feasibility of redo-TAVI in the self-expanding ACURATE neo2 valve: a computed tomography study.

机构信息

The Heart Center, Rigshospitalet, Copenhagen, Denmark.

Department of Cardiology, Hammersmith Hospital, Imperial College Healthcare NHS Trust London, London, United Kingdom.

出版信息

EuroIntervention. 2024 Nov 18;20(22):1405-1415. doi: 10.4244/EIJ-D-24-00367.

DOI:10.4244/EIJ-D-24-00367
PMID:39552483
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11556403/
Abstract

BACKGROUND

Redo-transcatheter aortic valve implantation (TAVI) may be unfeasible because of the risk of compromising coronary flow or coronary access by the pinned back leaflets of the index transcatheter aortic valve.

AIMS

We aimed to evaluate the feasibility of redo-TAVI using the balloon-expandable SAPIEN 3 (S3) implanted within the self-expanding ACURATE neo2 (ACn2) valve and to identify predictors associated with a high risk of compromising coronary flow.

METHODS

A total of 153 post-ACn2 TAVI cardiac computed tomography scans were analysed. Redo-TAVI using an S3 was simulated in two positions: S3 outflow to the ACn2 upper crown (low implant) and S3 outflow to the base of the ACn2 commissural posts (high implant). The risk for coronary flow compromise and inaccessibility was determined by the height of the neoskirt created by the pinned back leaflets and the valve-to-aorta distances.

RESULTS

At a low S3 implant position, risk of coronary flow compromise was predicted in only 8% of patients and this increased to 60% with a high S3 position. In accordance, coronary access was predicted to be unrestricted in 52% versus 13% of patients with a low versus high S3 implantation. Female sex, a small aortic annular dimension and a sinotubular junction-to-aortic annulus mean diameter ratio <1.15 were independent predictors associated with a high risk for coronary flow compromise.

CONCLUSIONS

The feasibility of redo-TAVI with an S3 in an ACn2 depends on the implant depth of the S3 and the geometry of the surrounding aorta. A low S3 implant may reduce the risk of coronary flow compromise and inaccessibility.

摘要

背景

由于先前经导管主动脉瓣置换术(TAVI)植入的瓣叶向后卷曲,可能会影响冠状动脉血流或冠状动脉入路,因此再次行经导管主动脉瓣置换术(redo-TAVI)可能无法实施。

目的

我们旨在评估在自膨式 ACURATE neo2(ACn2)瓣内植入球囊扩张式 SAPIEN 3(S3)行 redo-TAVI 的可行性,并确定与冠状动脉血流受损风险相关的预测因素。

方法

共分析了 153 例 ACn2 后 TAVI 心脏计算机断层扫描(CT)。在两种位置模拟了使用 S3 行 redo-TAVI:S3 流出至 ACn2 上冠(低位植入)和 S3 流出至 ACn2 瓣叶连合部支柱底部(高位植入)。通过后瓣叶向后卷曲形成的新裙边高度和瓣叶-主动脉距离来确定冠状动脉血流受损和不可接近的风险。

结果

在 S3 低位植入时,仅预测到 8%的患者存在冠状动脉血流受损风险,而 S3 高位植入时该风险增加至 60%。相应地,预测冠状动脉可接近的患者比例在 S3 低位植入时为 52%,而在 S3 高位植入时为 13%。女性、主动脉瓣环较小以及窦管交界-主动脉瓣环平均直径比<1.15 是与冠状动脉血流受损风险相关的独立预测因素。

结论

在 ACn2 内植入 S3 行 redo-TAVI 的可行性取决于 S3 的植入深度和周围主动脉的几何形状。S3 低位植入可能会降低冠状动脉血流受损和不可接近的风险。